Not yet recruitingNCT07829536Updated Sep 21, 2026

Silent Deployment and Prospective Evaluation of Zhunxin Agent for Emergency Chest Pain Assessment

An observational study in Chest Pain Center and Chest Pain, sponsored by Peking University Health Science Center. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Peking University Health Science Center · Observational

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 10,000
Ages: 18 Years and older
Sex: All

Study summary

The goal of this prospective, multicenter observational study is to evaluate how well Zhunxin Agent, an artificial intelligence system for chest pain assessment, performs in real-world emergency department settings. The study will include people who receive routine care for acute chest pain at participating hospitals.

The main questions this study aims to answer are:

How accurately can Zhunxin Agent identify serious causes of acute chest pain during routine emergency care?
How well can Zhunxin Agent distinguish people at different levels of clinical risk?

Zhunxin Agent will run in silent mode using clinical information collected during routine care. Its predictions will not be shown to treating clinicians and will not affect clinical decisions, diagnostic tests, or treatment.

Researchers will compare the predictions made by Zhunxin Agent with the final clinical diagnoses established through routine medical care.

Participants will:

Receive usual emergency care according to local clinical practice
Have routinely collected clinical data analyzed by Zhunxin Agent in the background
Receive no additional treatment or clinical intervention based on the Agent's predictions

Conditions studied

Chest Pain Center
Chest Pain

Browse trials for

Chest Pain 388

In context

Chest Pain

388 studies on the registry are indexed under Chest Pain; 64 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 489 across 167 observational studies indexed under Chest Pain.

Browse Chest Pain studies →

Lead sponsor

This is the only study on the registry with Peking University Health Science Center as lead sponsor.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Sampling method: Probability sample

Study population

The study population will consist of consecutive participants presenting with acute chest pain or symptoms suggestive of an acute chest pain condition to the emergency departments of participating hospitals during the prospective silent-deployment period. Participants will receive routine clinical care, while Zhunxin Agent will operate in the background without providing its predictions to treating clinicians.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants aged 18 years or older.
Participants presenting to a participating emergency department with acute chest pain, chest discomfort, or other symptoms that prompt clinical evaluation for an acute chest pain-related condition.
Participants undergoing an as part of routine clinical care during the index emergency department encounter.
Participants with at least one electrocardiogram that can be processed by Zhunxin Agent during the index emergency department encounter.
Participants with the routinely collected clinical information required for Zhunxin Agent to generate a valid prediction.
Participants presenting to a participating study site during the prospective study period.

Exclusion criteria

Exclusion Criteria:

Participants whose emergency department presentation does not involve evaluation for acute chest pain.
Participants without an obtained during the index emergency department encounter.
Participants for whom the electrocardiogram or other required input data are missing, corrupted, technically inaccessible, or otherwise unusable such that Zhunxin Agent cannot generate a valid prediction.
Duplicate records corresponding to the same emergency department encounter.
Participants whose clinical data cannot be used for research because of withdrawal of consent, refusal of data use where applicable, or other ethical, institutional, or regulatory restrictions.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram): A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 10,000 participants (estimated)
Patient registry: No

What researchers measure

Primary outcomes

Percentage of Participants Correctly Classified by Zhunxin Agent Across the Prespecified Acute Chest Pain Diagnostic Categories
Diagnostic accuracy will be reported as the percentage of evaluable participants for whom the final diagnostic classification generated by Zhunxin Agent matches the final reference diagnosis. The prespecified diagnostic categories are unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, aortic dissection, pulmonary embolism, and other causes of chest pain. The numerator will be the number of participants with a concordant Zhunxin Agent classification and reference diagnosis, and the denominator will be the total number of evaluable participants with both a valid Zhunxin Agent prediction and an available final reference diagnosis.
Time frame: Up to 30 days after emergency department presentation

Secondary outcomes

Diagnostic Performance of Zhunxin Agent for High-Risk Acute Chest Pain Conditions Assessed by Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, and AUROC
Diagnostic performance of Zhunxin Agent will be evaluated using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the area under the receiver operating characteristic curve (AUROC), using the final reference diagnosis as the reference standard. Prespecified high-risk acute chest pain conditions include ST-segment elevation myocardial infarction, aortic dissection, and pulmonary embolism. Sensitivity will be calculated as the proportion of participants with a target condition who are correctly identified by Zhunxin Agent. Specificity will be calculated as the proportion of participants without the target condition who are correctly identified as negative. PPV will be calculated as the proportion of participants with a positive Zhunxin Agent prediction who have the target condition, and NPV as the proportion of participants with a negative prediction who do not have the target condition. AUROC will be calculated using the predicted probabili
Time frame: Up to 30 days after emergency department presentation
Percentage of Participants With a Confirmed High-Risk Acute Chest Pain Condition Within Each Zhunxin Agent Risk Category
The clinical risk stratification performance of Zhunxin Agent will be evaluated by calculating the percentage of participants with a confirmed high-risk acute chest pain condition within each prespecified risk category. Zhunxin Agent classifies participants into low-, intermediate-, and high-risk categories for ST-segment elevation myocardial infarction, aortic dissection, and pulmonary embolism using prespecified thresholds. For each target condition and risk category, the numerator will be the number of participants with the corresponding final reference diagnosis, and the denominator will be the total number of participants assigned to that risk category. The proportions will be reported separately for the low-, intermediate-, and high-risk categories.
Time frame: Up to 30 days after emergency department presentation

Study locations

No study locations are listed for this record.

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2030, 48 months later.

Of 66 non-industry observational studies under Chest Pain, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 49. This study's planned 48 months is above that.

Counting every sponsor, half of 69 studies reached it within 25 months; a quarter within 16 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered: Sep 9, 2026
First posted: Sep 21, 2026
StartEst.: Sep 9, 2026
Primary completionEst.: Sep 9, 2030
CompletionEst.: Oct 9, 2030
Last update: Sep 21, 2026

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT07829536
Lead sponsor: Peking University Health Science Center
Responsible party: Yujie Xiao (Undergraduate, Peking University Health Science Center) — Principal investigator
First posted: Sep 21, 2026
Start date: Sep 9, 2026 (estimated)
Primary completion: Sep 9, 2030 (estimated)
Completion: Oct 9, 2030 (estimated)
Last update: Sep 21, 2026

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Chest Pain →

Start the discussion